Non-bonding energy directed designing of HDAC2 inhibitors through molecular dynamics simulation

References

• Abdel-Atty, M. M., Farag, N. A., Kassab, S. E., Serya, R. A. T., & Abouzid, K. A. M. (2014). Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents. Bioorganic Chemistry, 57, 65–82. https://doi.org/10.1016/j.bioorg.2014.08.006
   PubMed Web of Science ®Google Scholar
• Albani, D., Polito, L., & Forloni, G. (2010). Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: Experimental and genetic evidence. Journal of Alzheimer's Disease: JAD, 19(1), 11–26. https://doi.org/10.3233/JAD-2010-1215
   PubMed Web of Science ®Google Scholar
• Aldeghi, M., Heifetz, A., Bodkin, M. J., Knapp, S., & Biggin, P. C. (2017). Predictions of ligand selectivity from absolute binding free energy calculations. Journal of the American Chemical Society, 139(2), 946–957. https://doi.org/10.1021/jacs.6b11467
   PubMed Web of Science ®Google Scholar
• Al-Sanea, M. M., Gotina, L., Mohamed, M. F. A., Parambi, D. G. T., Gomaa, H. A. M., Mathew, B., Youssif, B. G. M., Alharbi, K. S., Elsayed, Z. M., Abdelgawad, M. A., & Eldehna, W. M. (2020). Design, synthesis and biological evaluation of new HDAC1 and HDAC2 inhibitors endowed with ligustrazine as a novel cap moiety. Drug Design, Development and Therapy, 14, 497–508. https://doi.org/10.2147/DDDT.S237957
   PubMed Web of Science ®Google Scholar
• Anh, D. T., Hai, P. T., Huong, L. T. T., Park, E. J., Jun, H. W., Kang, J. S., Kwon, J. H., Dung, D. T. M., Anh, V. T., Hue, V. T. M., Han, S. B., & Nam, N. H. (2020). Exploration of certain 1,3-oxazole- and 1,3-thiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents. Bioorganic Chemistry, 101(June), 103988. https://doi.org/10.1016/j.bioorg.2020.103988
   PubMedGoogle Scholar
• Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012). Epigenetic protein families: A new frontier for drug discovery. Nature Reviews Drug Discovery, 11(5), 384–400. https://doi.org/10.1038/nrd3674
   PubMed Web of Science ®Google Scholar
• Berendsen, H. J. C., van der Spoel, D., & van Drunen, R. (1995). GROMACS: A message-passing parallel molecular dynamics implementation. Computer Physics Communications, 91(1–3), 43–56. https://doi.org/10.1016/0010-4655(95)00042-E
   Web of Science ®Google Scholar
• Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., & Bourne, P. E. (2000). The protein data bank. Nucleic Acids Research, 28(1), 235–242. https://doi.org/10.1093/nar/28.1.235
   PubMed Web of Science ®Google Scholar
• Bhaumik, S. R., Smith, E., & Shilatifard, A. (2007). Covalent modifications of histones during development and disease pathogenesis. Nature Structural & Molecular Biology, 14(11), 1008–1016. https://doi.org/10.1038/nsmb1337
   PubMed Web of Science ®Google Scholar
• Bieliauskas, A. V., & Pflum, M. K. H. (2008). Isoform-selective histone deacetylase inhibitors. Chemical Society Reviews, 37(7), 1402–1413. https://doi.org/10.1039/b703830p
   PubMed Web of Science ®Google Scholar
• Böhm, H. J., & Schneider, G. (2003). Protein‐ligand interactions. In H.‐J. Böhm & G. Schneider (Eds.), Protein-ligand interactions: From molecular recognition to drug design. Wiley. https://doi.org/10.1002/3527601813
   Google Scholar
• Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006). Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery, 5(9), 769–784. https://doi.org/10.1038/nrd2133
   PubMed Web of Science ®Google Scholar
• Bressi, J. C., Jennings, A. J., Skene, R., Wu, Y., Melkus, R., De Jong, R., O’Connell, S., Grimshaw, C. E., Navre, M., & Gangloff, A. R. (2010). Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorganic & Medicinal Chemistry Letters, 20(10), 3142–3145. https://doi.org/10.1016/j.bmcl.2010.03.091
   PubMed Web of Science ®Google Scholar
• Case, D. A., Cheatham, T. E., Darden, T., Gohlke, H., Luo, R., Merz, K. M., Onufriev, A., Simmerling, C., Wang, B., & Woods, R. J. (2005). The Amber biomolecular simulation programs. Journal of Computational Chemistry, 26(16), 1668–1688. https://doi.org/10.1002/jcc.20290
   PubMed Web of Science ®Google Scholar
• Chen, Y. C. (2015). Beware of docking!. Trends in Pharmacological Sciences, 36(2), 78–95. https://doi.org/10.1016/j.tips.2014.12.001
   PubMed Web of Science ®Google Scholar
• Chou, C. J., Herman, D., & Gottesfeld, J. M. (2008). Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. The Journal of Biological Chemistry, 283(51), 35402–35409. https://doi.org/10.1074/jbc.M807045200
   PubMed Web of Science ®Google Scholar
• Choubey, S. K., & Jeyakanthan, J. (2018). Molecular dynamics and quantum chemistry-based approaches to identify isoform selective HDAC2 inhibitor - a novel target to prevent Alzheimer's disease. Journal of Receptor and Signal Transduction Research, 38(3), 266–278. https://doi.org/10.1080/10799893.2018.1476541
   PubMed Web of Science ®Google Scholar
• Cohen, I., Poręba, E., Kamieniarz, K., & Schneider, R. (2011). Histone modifiers in cancer: Friends or foes? Genes & Cancer, 2(6), 631–647. https://doi.org/10.1177/1947601911417176
   PubMedGoogle Scholar
• Coordinators, N. R. (2017). Database resources of the national center for biotechnology information. Nucleic Acids Research, 45(D1), D12–D17. https://doi.org/10.1093/nar/gkw1071
   PubMed Web of Science ®Google Scholar
• Cournia, Z., Allen, B., & Sherman, W. (2017). Relative binding free energy calculations in drug discovery: Recent advances and practical considerations. Journal of Chemical Information and Modeling, 57(12), 2911–2937. https://doi.org/10.1021/acs.jcim.7b00564
   PubMed Web of Science ®Google Scholar
• Daniel, L., Gotsbacher, M. P., Richardson-Sanchez, T., Tieu, W., & Codd, R. (2019). Exploring hydroxamic acid inhibitors of HDAC1 and HDAC2 using small molecule tools and molecular or homology modelling. Bioorganic & Medicinal Chemistry Letters, 29(18), 2581–2586. https://doi.org/10.1016/j.bmcl.2019.08.002
   PubMed Web of Science ®Google Scholar
• de Ruijter, A. J. M., van Gennip, A. H., Caron, H. N., Kemp, S., & van Kuilenburg, A. B. P. (2003). Histone deacetylases (HDACs): Characterization of the classical HDAC family. The Biochemical Journal, 370(Pt 3), 737–749. https://doi.org/10.1042/BJ20021321
   PubMed Web of Science ®Google Scholar
• Deschamps, N., Simões-Pires, C. A., Carrupt, P. A., & Nurisso, A. (2015). How the flexibility of human histone deacetylases influences ligand binding: An overview. Drug Discovery Today, 20(6), 736–742. https://doi.org/10.1016/j.drudis.2015.01.004
   PubMed Web of Science ®Google Scholar
• Dewaker, V., Srivastava, A. K., Arora, A., & Prabhakar, Y. S. (2020a). Investigation of HDAC8-ligands’ intermolecular forces through molecular dynamics simulations: Profiling of non-bonding energies to design potential compounds as new anti-cancer agents. Journal of Biomolecular Structure & Dynamics, 1–26. https://doi.org/10.1080/07391102.2020.1780940
   Google Scholar
• Dewaker, V., Srivastava, P. N., Verma, S., & Prabhakar, Y. S. (2020b). Molecular dynamics study of HDAC8-largazole analogues co-crystals for designing potential anticancer compounds. Journal of Biomolecular Structure & Dynamics, 38(4), 1197–1213. https://doi.org/10.1080/07391102.2019.1598497
   PubMed Web of Science ®Google Scholar
• Di Gennaro, E., Bruzzese, F., Caraglia, M., Abruzzese, A., & Budillon, A. (2004). Acetylation of proteins as novel target for antitumor therapy: Review article. Amino Acids, 26(4), 435–441. https://doi.org/10.1007/s00726-004-0087-3
   PubMed Web of Science ®Google Scholar
• Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K., & Benz, C. C. (2005). Clinical development of histone deacetylase inhibitors as anticancer agents. Annual Review of Pharmacology and Toxicology, 45(1), 495–528. https://doi.org/10.1146/annurev.pharmtox.45.120403.095825
   PubMed Web of Science ®Google Scholar
• Du, Y., Tang, G., & Yuan, W. (2020). Suppression of HDAC2 by sodium butyrate alleviates apoptosis of kidney cells in db/db mice and HG‐induced NRK‐52E cells. International Journal of Molecular Medicine, 45(1), 210–222. https://doi.org/10.3892/ijmm.2019.4397
   PubMed Web of Science ®Google Scholar
• Falkenberg, K. J., & Johnstone, R. W. (2014). Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nature Reviews Drug Discovery, 13(9), 673–691. https://doi.org/10.1038/nrd4360
   PubMed Web of Science ®Google Scholar
• Fournier, J.-F., Bhurruth-Alcor, Y., Musicki, B., Aubert, J., Aurelly, M., Bouix-Peter, C., Bouquet, K., Chantalat, L., Delorme, M., Drean, B., Duvert, G., Fleury-Bregeot, N., Gauthier, B., Grisendi, K., Harris, C. S., Hennequin, L. F., Isabet, T., Joly, F., Lafitte, G., … Tomas, L. (2018). Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma. Bioorganic & Medicinal Chemistry Letters, 28(17), 2985–2992. https://doi.org/10.1016/j.bmcl.2018.06.029
   PubMed Web of Science ®Google Scholar
• Ganai, S. A. (2021). Characterizing binding intensity and energetic features of histone deacetylase inhibitor pracinostat towards class I HDAC isozymes through futuristic drug designing strategy. In Silico Pharmacology, 9(1), 18. https://doi.org/10.1007/s40203-021-00077-y. eCollection 2021
   Google Scholar
• Ganai, S. A., Abdullah, E., Rashid, R., & Altaf, M. (2017). Combinatorial in silico strategy towards identifying potential hotspots during inhibition of structurally identical HDAC1 and HDAC2 enzymes for effective chemotherapy against neurological disorders. Frontiers in Molecular Neuroscience, 10(November), 317–357. https://doi.org/10.3389/fnmol.2017.00357
   PubMedGoogle Scholar
• Ganai, S. A., Srinivasan, P., Rajamanikandan, S., Shah, B. A., Mohan, S., Gani, M., Padder, B. A., Qadri, R. A., Bhat, M. A., Baba, Z. A., & Yatoo, M. A. (2021). Delineating binding potential, stability of sulforaphane-N-acetyl-cysteine in the active site of histone deacetylase 2 and testing its cytotoxicity against distinct cancer lines through stringent molecular dynamics, DFT and cell-based assays. Chemical Biology & Drug Design, 98(3), 363–376. https://doi.org/10.1111/cbdd.13854
   PubMed Web of Science ®Google Scholar
• Gillette, T. G. (2021). HDAC inhibition in the heart: Erasing hidden fibrosis. In Circulation (pp. 1891–1893). Lippincott Williams & Wilkins Hagerstown. https://doi.org/10.1161/CIRCULATIONAHA.121.054262
   Google Scholar
• Gordon, J. C., Myers, J. B., Folta, T., Shoja, V., Heath, L. S., & Onufriev, A. (2005). H++: A server for estimating pKas and adding missing hydrogens to macromolecules. Nucleic Acids Research, 33(Suppl 2), W368–371. https://doi.org/10.1093/nar/gki464
   Google Scholar
• Grootenhuis, P. D. J., & van Galen, P. J. M. (1995). Correlation of binding affinities with non-bonded interaction energies of thrombin-inhibitor complexes. Acta Crystallographica Section D, Biological Crystallography, 51(Pt 4), 560–566. https://doi.org/10.1107/S0907444994011686
   PubMedGoogle Scholar
• Grozinger, C. M., & Schreiber, S. L. (2002). Deacetylase enzymes: Biological functions and the use of small-molecule inhibitors. Chemistry & Biology, 9(1), 3–16. https://doi.org/10.1016/S1074-5521(02)00092-3
   PubMedGoogle Scholar
• Haberland, M., Montgomery, R. L., & Olson, E. N. (2009). The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nature Reviews Genetics, 10(1), 32–42. https://doi.org/10.1038/nrg2485
   PubMed Web of Science ®Google Scholar
• Hassanzadeh, M., Bagherzadeh, K., & Amanlou, M. (2016). A comparative study based on docking and molecular dynamics simulations over HDAC-tubulin dual inhibitors. Journal of Molecular Graphics & Modelling, 70, 170–180. https://doi.org/10.1016/j.jmgm.2016.10.007
   PubMed Web of Science ®Google Scholar
• Hess-Stumpp, H. (2005). Histone deacetylase inhibitors and cancer: From cell biology to the clinic. European Journal of Cell Biology, 84(2–3), 109–121. https://doi.org/10.1016/j.ejcb.2004.12.010
   PubMed Web of Science ®Google Scholar
• Hieu, D. T., Anh, D. T., Hai, P. T., Thuan, N. T., Huong, L. T. T., Park, E. J., Young Ji, A., Soon Kang, J., Phuong Dung, P. T., Han, S. B., & Nam, N. H. (2019). Quinazolin-4(3H)-one-based hydroxamic acids: Design, synthesis and evaluation of histone deacetylase inhibitory effects and cytotoxicity. Chemistry and Biodiversity, 16(4), e1800502. https://doi.org/10.1002/cbdv.201800502
   Google Scholar
• Hildmann, C., Riester, D., & Schwienhorst, A. (2007). Histone deacetylases-an important class of cellular regulators with a variety of functions. Applied Microbiology and Biotechnology, 75(3), 487–497. https://doi.org/10.1007/s00253-007-0911-2
   PubMed Web of Science ®Google Scholar
• Holloway, M. K., Wai, J. M., Halgren, T. A., Fitzgerald, P. M. D., Vacca, J. P., Dorsey, B. D., Levin, R. B., Thompson, W. J., Chen, L. J., deSolms, S. J., Gaffin, N., Ghosh, A. K., Giuliani, E. A., Graham, S. L., Guare, J. P., Hungate, R. W., Lyle, T. A., Sanders, W. M., Tucker, T. J., … Zugay, J. A. (1995). A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site. Journal of Medicinal Chemistry, 38(2), 305–317. https://doi.org/10.1021/jm00002a012
   PubMed Web of Science ®Google Scholar
• Huang, B. H., Laban, M., Leung, C. H. W., Lee, L., Lee, C. K., Salto-Tellez, M., Raju, G. C., & Hooi, S. C. (2005). Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death and Differentiation, 12(4), 395–404. https://doi.org/10.1038/sj.cdd.4401567
   PubMed Web of Science ®Google Scholar
• Humphrey, W., Dalke, A., & Schulten, K. (1996). VMD: Visual molecular dynamics. Journal of Molecular Graphics, 14(1), 33–38. https://doi.org/10.1016/0263-7855(96)00018-5
   PubMedGoogle Scholar
• Johnstone, R. W. (2002). Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nature Reviews Drug Discovery, 1(4), 287–299. https://doi.org/10.1038/nrd772
   PubMed Web of Science ®Google Scholar
• Kalyaanamoorthy, S., & Chen, Y. P. P. (2013). Energy based pharmacophore mapping of HDAC inhibitors against class i HDAC enzymes. Biochimica et Biophysica Acta, 1834(1), 317–328. https://doi.org/10.1016/j.bbapap.2012.08.009
   PubMed Web of Science ®Google Scholar
• Kassem, S., Ahmed, M., El-Sheikh, S., & Barakat, K. H. (2015). Entropy in bimolecular simulations: A comprehensive review of atomic fluctuations-based methods. Journal of Molecular Graphics & Modelling, 62, 105–117. https://doi.org/10.1016/j.jmgm.2015.09.010
   PubMed Web of Science ®Google Scholar
• Kavianpour, P., Gemmell, M. C. M., Kahlert, J. U., & Rendina, L. M. (2020). Histone deacetylase 2 (HDAC2) inhibitors containing boron. ChemBioChem, 21(19), 2786–2791. https://doi.org/10.1002/cbic.202000131
   PubMed Web of Science ®Google Scholar
• Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., Finn, P. W., Collins, L. S., Tumber, A., Ritchie, J. W., Jensen, P. B., Lichenstein, H. S., & Sehested, M. (2008). Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. The Biochemical Journal, 409(2), 581–589. https://doi.org/10.1042/BJ20070779
   PubMed Web of Science ®Google Scholar
• Khoury, G. A., Baliban, R. C., & Floudas, C. A. (2011). Proteome-wide post-translational modification statistics: Frequency analysis and curation of the swiss-prot database. Scientific Reports, 1(1), 1–5. https://doi.org/10.1038/srep00090
   PubMedGoogle Scholar
• Krämer, O. H. (2009). HDAC2: A critical factor in health and disease. Trends in Pharmacological Sciences, 30(12), 647–655. https://doi.org/10.1016/j.tips.2009.09.007
   PubMed Web of Science ®Google Scholar
• Kunze, M. B. A., Wright, D. W., Werbeck, N. D., Kirkpatrick, J., Coveney, P. V., & Hansen, D. F. (2013). Loop interactions and dynamics tune the enzymatic activity of the human histone deacetylase 8. Journal of the American Chemical Society, 135(47), 17862–17868. https://doi.org/10.1021/ja408184x
   PubMed Web of Science ®Google Scholar
• Lalonde, M. E., Cheng, X., & Côté, J. (2014). Histone target selection within chromatin: An exemplary case of teamwork. Genes & Development, 28(10), 1029–1041. https://doi.org/10.1101/gad.236331.113
   PubMed Web of Science ®Google Scholar
• Lane, A. A., & Chabner, B. A. (2009). Histone deacetylase inhibitors in cancer therapy. Journal of Clinical Oncology, 27(32), 5459–5468. https://doi.org/10.1200/JCO.2009.22.1291
   PubMed Web of Science ®Google Scholar
• Laubach, J. P., Moreau, P., San-Miguel, J. F., & Richardson, P. G. (2015). Panobinostat for the treatment of multiple myeloma. Clinical Cancer Research, 21(21), 4767–4773. https://doi.org/10.1158/1078-0432.CCR-15-0530
   PubMed Web of Science ®Google Scholar
• Lauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., Ortwine, D. F., Gunzner, J., Modrusan, Z., Neumann, L., Koth, C. M., Lupardus, P. J., Kaminker, J. S., Heise, C. E., & Steiner, P. (2013). Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. The Journal of Biological Chemistry, 288(37), 26926–26943. https://doi.org/10.1074/jbc.M113.490706
   PubMed Web of Science ®Google Scholar
• Lee, H. Z., Kwitkowski, V. E., Del Valle, P. L., Ricci, M. S., Saber, H., Habtemariam, B. A., Bullock, J., Bloomquist, E., Shen, Y. L., Chen, X. H., Brown, J., Mehrotra, N., Dorff, S., Charlab, R., Kane, R. C., Kaminskas, E., Justice, R., Farrell, A. T., & Pazdur, R. (2015). FDA approval: Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clinical Cancer Research, 21(12), 2666–2670. https://doi.org/10.1158/1078-0432.CCR-14-3119
   PubMed Web of Science ®Google Scholar
• Li, Z., Huang, Y., Wu, Y., Chen, J., Wu, D., Zhan, C. G., & Luo, H. B. (2019). Absolute binding free energy calculation and design of a subnanomolar inhibitor of phosphodiesterase-10. Journal of Medicinal Chemistry, 62(4), 2099–2111. https://doi.org/10.1021/acs.jmedchem.8b01763
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A. (2000). Drug-like properties and the causes of poor solubility and poor permeability. Journal of Pharmacological and Toxicological Methods, 44(1), 235–249. https://doi.org/10.1016/S1056-8719(00)00107-6
   PubMed Web of Science ®Google Scholar
• Liu, H., & Hou, T. (2016). CaFE: A tool for binding affinity prediction using end-point free energy methods. Bioinformatics (Oxford, England), 32(14), 2216–2218. https://doi.org/10.1093/bioinformatics/btw215
   PubMed Web of Science ®Google Scholar
• Lobera, M., Madauss, K. P., Pohlhaus, D. T., Wright, Q. G., Trocha, M., Schmidt, D. R., Baloglu, E., Trump, R. P., Head, M. S., Hofmann, G. A., Murray-Thompson, M., Schwartz, B., Chakravorty, S., Wu, Z., Mander, P. K., Kruidenier, L., Reid, R. A., Burkhart, W., Turunen, B. J., … Nolan, M. A. (2013). Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nature Chemical Biology, 9(5), 319–325. https://doi.org/10.1038/nchembio.1223
   PubMed Web of Science ®Google Scholar
• López, J. E., Sullivan, E. D., & Fierke, C. A. (2016). Metal-dependent deacetylases: Cancer and epigenetic regulators. ACS Chemical Biology, 11(3), 706–716. https://doi.org/10.1021/acschembio.5b01067
   PubMed Web of Science ®Google Scholar
• Lu, X., Ning, Z., Li, Z., Cao, H., & Wang, X. (2016). Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China. Intractable & Rare Diseases Research, 5(3), 185–191.
   PubMed Web of Science ®Google Scholar
• MacKerell, A. D., Bashford, D., Bellott, M., Dunbrack, R. L., Evanseck, J. D., Field, M. J., Fischer, S., Gao, J., Guo, H., Ha, S., Joseph-McCarthy, D., Kuchnir, L., Kuczera, K., Lau, F. T., Mattos, C., Michnick, S., Ngo, T., Nguyen, D. T., Prodhom, B., … Karplus, M. (1998). All-atom empirical potential for molecular modeling and dynamics studies of proteins. The Journal of Physical Chemistry B, 102(18), 3586–3616. https://doi.org/10.1021/jp973084f
   PubMed Web of Science ®Google Scholar
• Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007). FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. The Oncologist, 12(10), 1247–1252. https://doi.org/10.1634/theoncologist.12-10-1247
   PubMed Web of Science ®Google Scholar
• Marks, P. a., & Dokmanovic, M. (2005). Histone deacetylase inhibitors: Discovery and development as anticancer agents. Expert Opinion on Investigational Drugs, 14(12), 1497–1511. https://doi.org/10.1517/13543784.14.12.1497
   PubMed Web of Science ®Google Scholar
• Martínez-Pacheco, H., Espinosa-Raya, J., Picazo, O., Roldán-Roldán, G., Viñas-Bravo, O., & Ramírez-Galicia, G. (2018). Design (Docking and QSAR Studies) and synthesis of histone deacetylase 2 (HDAC2) inhibitors series. Medicinal Chemistry Research, 27(1), 206–223. https://doi.org/10.1007/s00044-017-2051-2
   Web of Science ®Google Scholar
• Melesina, J., Praetorius, L., Simoben, C. V., Robaa, D., & Sippl, W. (2018). Design of selective histone deacetylase inhibitors: Rethinking classical pharmacophore. Future Medicinal Chemistry, 10(13), 1537–1540. https://doi.org/10.4155/fmc-2018-0125
   PubMed Web of Science ®Google Scholar
• Methot, J. L., Chakravarty, P. K., Chenard, M., Close, J., Cruz, J. C., Dahlberg, W. K., Fleming, J., Hamblett, C. L., Hamill, J. E., Harrington, P., Harsch, A., Heidebrecht, R., Hughes, B., Jung, J., Kenific, C. M., Kral, A. M., Meinke, P. T., Middleton, R. E., Ozerova, N., … Miller, T. A. (2008a). Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorganic & Medicinal Chemistry Letters, 18(3), 973–978. https://doi.org/10.1016/j.bmcl.2007.12.031
   PubMed Web of Science ®Google Scholar
• Methot, J. L., Hamblett, C. L., Mampreian, D. M., Jung, J., Harsch, A., Szewczak, A. A., Dahlberg, W. K., Middleton, R. E., Hughes, B., Fleming, J. C., Wang, H., Kral, A. M., Ozerova, N., Cruz, J. C., Haines, B., Chenard, M., Kenific, C. M., Secrist, J. P., & Miller, T. A. (2008b). SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorganic & Medicinal Chemistry Letters, 18(23), 6104–6109. https://doi.org/10.1016/j.bmcl.2008.10.052
   PubMed Web of Science ®Google Scholar
• Methot, J. L., Hoffman, D. M., Witter, D. J., Stanton, M. G., Harrington, P., Hamblett, C., Siliphaivanh, P., Wilson, K., Hubbs, J., Heidebrecht, R., Kral, A. M., Ozerova, N., Fleming, J. C., Wang, H., Szewczak, A. A., Middleton, R. E., Hughes, B., Cruz, J. C., Haines, B. B., … Miller, T. A. (2014). Delayed and prolonged histone hyperacetylation with a selective HDAC1/HDAC2 inhibitor. ACS Medicinal Chemistry Letters, 5(4), 340–345. https://doi.org/10.1021/ml4004233
   PubMed Web of Science ®Google Scholar
• Micelli, C., & Rastelli, G. (2015). Histone deacetylases: Structural determinants of inhibitor selectivity. Drug Discovery Today, 20(6), 718–735. https://doi.org/10.1016/j.drudis.2015.01.007
   PubMed Web of Science ®Google Scholar
• Miller, B. R., McGee, T. D., Swails, J. M., Homeyer, N., Gohlke, H., & Roitberg, A. E. (2012). MMPBSA.py: An efficient program for end-state free energy calculations. Journal of Chemical Theory and Computation, 8(9), 3314–3321. https://doi.org/10.1021/ct300418h
   PubMed Web of Science ®Google Scholar
• Mohamed, M. F. A., Youssif, B. G. M., Shaykoon, M. S. A., Abdelrahman, M. H., Elsadek, B. E. M., Aboraia, A. S., & Abuo-Rahma, G. E. D. A. (2019). Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors. Bioorganic Chemistry, 91(December 2018), 103127. https://doi.org/10.1016/j.bioorg.2019.103127
   PubMedGoogle Scholar
• Molecular Operating Environment (MOE). (n.d.). Version 2008. Chemical Computing Group Inc. http://www.chemcomp.com.
   Google Scholar
• Mottamal, M., Zheng, S., Huang, T. L., & Wang, G. (2015). Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules (Basel, Switzerland), 20(3), 3898–3941. https://doi.org/10.3390/molecules20033898
   PubMed Web of Science ®Google Scholar
• Nair, S. S., & Kumar, R. (2012). Chromatin remodeling in Cancer: A gateway to regulate gene transcription. Molecular Oncology, 6(6), 611–619. https://doi.org/10.1016/j.molonc.2012.09.005
   PubMed Web of Science ®Google Scholar
• Ning, C., Bi, Y., He, Y., Huang, W., Liu, L., Li, Y., Zhang, S., Liu, X., & Yu, N. (2013). Design, synthesis and biological evaluation of di-substituted cinnamic hydroxamic acids bearing urea/thiourea unit as potent histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters, 23(23), 6432–6435. https://doi.org/10.1016/j.bmcl.2013.09.051
   PubMed Web of Science ®Google Scholar
• Ouaïssi, M., Giger, U., Sielezneff, I., Pirrò, N., Sastre, B., & Ouaissi, A. (2011). Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer. Journal of Biomedicine & Biotechnology, 2011, 315939. https://doi.org/10.1155/2011/315939
   PubMedGoogle Scholar
• Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004). UCSF Chimera-a visualization system for exploratory research and analysis. Journal of Computational Chemistry, 25(13), 1605–1612. https://doi.org/10.1002/jcc.20084
   PubMed Web of Science ®Google Scholar
• Pham-The, H., Casañola-Martin, G., Diéguez-Santana, K., Nguyen-Hai, N., Ngoc, N. T., Vu-Duc, L., & Le-Thi-Thu, H. (2017). Quantitative structure-activity relationship analysis and virtual screening studies for identifying HDAC2 inhibitors from known HDAC bioactive chemical libraries. SAR and QSAR in Environmental Research, 28(3), 199–220. https://doi.org/10.1080/1062936X.2017.1294198
   PubMed Web of Science ®Google Scholar
• Phillips, J., Hardy, D., Isgro, T., Phillips, J., Villa, E., Yu, H., Tanner, D., Liu, Y., Wu, Z., & Hardy, D. (2017). Namd Tutorial. April, 1–120.
   Google Scholar
• Qi, Z., Wang, C., Jiang, J., & Wu, C. (2018). Novel C15 triene triazole, D-A derivatives anti-HepG2, and as HDAC2 inhibitors: A synergy study. International Journal of Molecular Sciences, 19(10), 3184. https://doi.org/10.3390/ijms19103184
   PubMed Web of Science ®Google Scholar
• Qin, H. T., Li, H. Q., & Liu, F. (2017). Selective histone deacetylase small molecule inhibitors: Recent progress and perspectives. Expert Opinion on Therapeutic Patents, 27(5), 621–636. https://doi.org/10.1080/13543776.2017.1276565
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama, A., Kantarjian, H., Estrov, Z., Borthakur, G., Cortes, J., & Verstovsek, S. (2012). Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leukemia Research, 36(9), 1124–1127. https://doi.org/10.1016/j.leukres.2012.03.003
   PubMed Web of Science ®Google Scholar
• Reddy, D. N., Ballante, F., Chuang, T., Pirolli, A., Marrocco, B., & Marshall, G. R. (2016). Design and synthesis of simplified largazole analogues as isoform-selective human lysine deacetylase inhibitors. Journal of Medicinal Chemistry, 59(4), 1613–1633. https://doi.org/10.1021/acs.jmedchem.5b01632
   PubMed Web of Science ®Google Scholar
• Rikimaru, T., Taketomi, A., Yamashita, Y. I., Shirabe, K., Hamatsu, T., Shimada, M., & Maehara, Y. (2007). Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology, 72(1–2), 69–74. https://doi.org/10.1159/000111106
   PubMed Web of Science ®Google Scholar
• Ropero, S., & Esteller, M. (2007). The role of histone deacetylases (HDACs) in human cancer. Molecular Oncology, 1(1), 19–25. https://doi.org/10.1016/j.molonc.2007.01.001
   PubMed Web of Science ®Google Scholar
• Schroeder, F. A., Chonde, D. B., Riley, M. M., Moseley, C. K., Granda, M. L., Wilson, C. M., Wagner, F. F., Zhang, Y. L., Gale, J., Holson, E. B., Haggarty, S. J., & Hooker, J. M. (2013). FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors. Neuroscience Letters, 550, 119–124. https://doi.org/10.1016/j.neulet.2013.06.016
   PubMed Web of Science ®Google Scholar
• Shahbazian, M. D., & Grunstein, M. (2007). Functions of site-specific histone acetylation and deacetylation. Annual Review of Biochemistry, 76(1), 75–100. https://doi.org/10.1146/annurev.biochem.76.052705.162114
   PubMed Web of Science ®Google Scholar
• Sharma, S., Kelly, T. K., & Jones, P. A. (2010). Epigenetics in cancer. Carcinogenesis, 31(1), 27–36. https://doi.org/10.1093/carcin/bgp220
   PubMed Web of Science ®Google Scholar
• Simone, C., & Peserico, A. (2011). Physical and functional HAT/HDAC interplay regulates protein acetylation balance. Journal of Biomedicine & Biotechnology, 2011(Table 1), 371832. https://doi.org/10.1155/2011/371832
   PubMedGoogle Scholar
• Singh, N., & Li, W. (2020). Absolute binding free energy calculations for highly flexible protein MDM2 and its inhibitors. International Journal of Molecular Sciences, 21(13), 4765–4715. https://doi.org/10.3390/ijms21134765
   PubMed Web of Science ®Google Scholar
• Sixto-López, Y., Bello, M., & Correa-Basurto, J. (2019). Insights into structural features of HDAC1 and its selectivity inhibition elucidated by Molecular dynamic simulation and Molecular Docking. Journal of Biomolecular Structure & Dynamics, 37(3), 584–610. https://doi.org/10.1080/07391102.2018.1441072
   PubMed Web of Science ®Google Scholar
• Song, J., Noh, J. H., Lee, J. H., Eun, J. W., Ahn, Y. M., Kim, S. Y., Hyung Lee, S., Park, W. S., Yoo, N. J., Lee, J. Y., & Nam, S. W. (2005). Increased expression of histone deacetylase 2 is found in human gastric cancer. Acta Pathologica, Microbiologica, et Immunologica Scandinavica, 113(4), 264–268. https://doi.org/10.1111/j.1600-0463.2005.apm_04.x
   PubMed Web of Science ®Google Scholar
• Spange, S., Wagner, T., Heinzel, T., & Krämer, O. H. (2009). Acetylation of non-histone proteins modulates cellular signalling at multiple levels. The International Journal of Biochemistry & Cell Biology, 41(1), 185–198. https://doi.org/10.1016/j.biocel.2008.08.027
   PubMed Web of Science ®Google Scholar
• Sterner, D. E., & Berger, S. L. (2000). Acetylation of histones and transcription-related factors. Microbiology and Molecular Biology Reviews, 64(2), 435–459. https://doi.org/10.1128/mmbr.64.2.435-459.2000
   PubMed Web of Science ®Google Scholar
• Stoddard, S. V., May, X. A., Rivas, F., Dodson, K., Vijayan, S., Adhika, S., Parker, K., & Watkins, D. L. (2019). Design of potent panobinostat histone deacetylase inhibitor derivatives: Molecular considerations for enhanced isozyme selectivity between HDAC2 and HDAC8. Molecular Informatics, 38(3), 1800080–1800089. https://doi.org/10.1002/minf.201800080
   Web of Science ®Google Scholar
• Stote, R. H., & Karplus, M. (1995). Zinc binding in proteins and solution: A simple but accurate nonbonded representation. Proteins, 23(1), 12–31. https://doi.org/10.1002/prot.340230104
   PubMed Web of Science ®Google Scholar
• Tang, J., Yan, H., & Zhuang, S. (2013). Histone deacetylases as targets for treatment of multiple diseases. Clinical Science (London, England: 1979), 124(11), 651–662. https://doi.org/10.1042/CS20120504
   PubMed Web of Science ®Google Scholar
• Tilekar, K., Upadhyay, N., Jänsch, N., Schweipert, M., Mrowka, P., Meyer-Almes, F. J., & Ramaa, C. S. (2020). Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines. Bioorganic Chemistry, 95(October 2019), 103522. https://doi.org/10.1016/j.bioorg.2019.103522
   PubMedGoogle Scholar
• Trot, O., & Olson, A. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461. https://doi.org/10.1002/jcc
   PubMed Web of Science ®Google Scholar
• VanderMolen, K. M., McCulloch, W., Pearce, C. J., & Oberlies, N. H. (2011). Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): A natural product recently approved for cutaneous T-cell lymphoma. The Journal of Antibiotics, 64(8), 525–531. https://doi.org/10.1038/ja.2011.35
   PubMed Web of Science ®Google Scholar
• Vanommeslaeghe, K., Hatcher, E., Acharya, C., Kundu, S., Zhong, S., Shim, J., Darian, E., Guvench, O., Lopes, P., Vorobyov, I., & Mackerell, A. D. (2010). CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. Journal of Computational Chemistry, 31(4), 671–690. https://doi.org/10.1002/jcc
   PubMed Web of Science ®Google Scholar
• Vanommeslaeghe, K., & MacKerell, A. D. (2012). Automation of the CHARMM general force field (CGenFF) I: Bond perception and atom typing. Journal of Chemical Information and Modeling, 52(12), 3144–3154. https://doi.org/10.1021/ci300363c
   PubMed Web of Science ®Google Scholar
• Vanommeslaeghe, K., Raman, E. P., & MacKerell, A. D. (2012). Automation of the CHARMM General Force Field (CGenFF) II: Assignment of bonded parameters and partial atomic charges. Journal of Chemical Information and Modeling, 52(12), 3155–3168. https://doi.org/10.1021/ci3003649
   PubMed Web of Science ®Google Scholar
• Wagner, F. F., Weïwer, M., Steinbacher, S., Schomburg, A., Reinemer, P., Gale, J. P., Campbell, A. J., Fisher, S. L., Zhao, W. N., Reis, S. A., Hennig, K. M., Thomas, M., Müller, P., Jefson, M. R., Fass, D. M., Haggarty, S. J., Zhang, Y. L., & Holson, E. B. (2016). Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors. Bioorganic & Medicinal Chemistry, 24(18), 4008–4015. https://doi.org/10.1016/j.bmc.2016.06.040
   PubMed Web of Science ®Google Scholar
• Wagner, F. F., Zhang, Y.-L., Fass, D. M., Joseph, N., Gale, J. P., Weïwer, M., McCarren, P., Fisher, S. L., Kaya, T., Zhao, W.-N., Reis, S. A., Hennig, K. M., Thomas, M., Lemercier, B. C., Lewis, M. C., Guan, J. S., Moyer, M. P., Scolnick, E., Haggarty, S. J., Tsai, L.-H., & Holson, E. B. (2015). Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers. Chemical Science, 6(1), 804–815. https://doi.org/10.1039/C4SC02130D
   PubMed Web of Science ®Google Scholar
• Wang, G. G., Allis, C. D., & Chi, P. (2007). Chromatin remodeling and cancer, part I: Covalent histone modifications. Trends in Molecular Medicine, 13(9), 363–372. https://doi.org/10.1016/j.molmed.2007.07.003
   PubMed Web of Science ®Google Scholar
• Wilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M. (2006). Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. The Journal of Biological Chemistry, 281(19), 13548–13558. https://doi.org/10.1074/jbc.M510023200
   PubMed Web of Science ®Google Scholar
• Xu, Z., Yang, Y., Mai, X., Liu, B., Xiong, Y., Feng, L., Liao, Y., Zhang, Y., Wang, H., Ouyang, L., & Liu, S. (2018). Syntheses and biological evaluation of novel hydroxamic acid derivatives containing purine moiety as histone deacetylase inhibitors. Chemical & Pharmaceutical Bulletin, 66(4), 439–451. https://doi.org/10.1248/cpb.c17-00997
   PubMed Web of Science ®Google Scholar
• Yu, Z., Li, P., & Merz, K. M. (2018). Extended zinc AMBER force field (EZAFF). Journal of Chemical Theory and Computation, 14(1), 242–254. https://doi.org/10.1021/acs.jctc.7b00773
   PubMed Web of Science ®Google Scholar
• Zhou, H., Wang, C., Ye, J., Chen, H., & Tao, R. (2017). Design, virtual screening, molecular docking and molecular dynamics studies of novel urushiol derivatives as potential HDAC2 selective inhibitors. Gene, 637(August), 63–71. https://doi.org/10.1016/j.gene.2017.09.034
   PubMedGoogle Scholar
• Zhu, P., Martin, E., Mengwasser, J., Schlag, P., Janssen, K. P., & Göttlicher, M. (2004). Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell, 5(5), 455–463. https://doi.org/10.1016/S1535-6108(04)00114-X
   PubMed Web of Science ®Google Scholar